Business Context and Reporting Period
This Form 8-K filing by Atricure, Inc. covers the date of March 11, 2013. The report details a corporate governance event involving the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Robert "Bob" S. White as a director, effective March 11, 2013. Mr. White has been nominated for re-election at the 2013 Annual Meeting of Stockholders. The Board has determined that Mr. White qualifies as an independent director under Nasdaq listing standards.
Outlook, Risks, and Management Commentary
Management highlights Mr. White's extensive background in the medical technology industry, including over 25 years of experience in commercial expansion, operations, and sales. He currently serves as President and CEO of TYRX and previously held senior leadership roles at Medtronic, Inc., including President of Medtronic Kyphon and President of Physio Control. There are no undisclosed arrangements or transactions between the Company and Mr. White requiring disclosure under Item 404(a) of Regulation S-K. His compensation will align with the Company's existing policies for non-employee directors.
Investor Verification Checklist
- Verify the independence status of Robert S. White against current Nasdaq listing standards.
- Review the Company's proxy statement filed on April 13, 2012, for details on director compensation policies.
- Confirm the date and agenda for the 2013 Annual Meeting of Stockholders where Mr. White will stand for re-election.
- Examine Exhibit 99.1 for the full text of the press release announcing the appointment.